<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Immunosuppressants: skin disease; Pimecrolimus; Tacrolimus: eczema; Ciclosporin: eczema; Ciclosporin: psoriasis; Azathioprine: eczema; Mycophenolate mofetil: eczema; Methotrexate: psoriasis; Cytokine modulators: psoriasis; Etanercept: psoriasis; Adalimumab: psoriasis; Infliximab: psoriasis; Ustekinumab" /><meta name="IX" content="Immunosuppressants: skin disease; Pimecrolimus; Tacrolimus: eczema; Ciclosporin: eczema; Ciclosporin: psoriasis; Azathioprine: eczema; Mycophenolate mofetil: eczema; Methotrexate: psoriasis; Cytokine modulators: psoriasis; Etanercept: psoriasis; Adalimumab: psoriasis; Infliximab: psoriasis; Ustekinumab" /><title>13.5.3 Drugs affecting the immune response: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP7766-drugs-affecting-the-immune-response.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP7766-drugs-affecting-the-immune-response.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP7766-drugs-affecting-the-immune-response.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP7449-skin.htm">13 Skin</a> &gt; <a href="PHP7686-preparations-for-eczema-and-psoriasis.htm">13.5 Preparations for eczema and psoriasis</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP7757-acitretin.htm" title="Previous: ACITRETIN">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP7770-azathioprine.htm" title="Next: AZATHIOPRINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>13.5.3 </span>Drugs affecting the immune response</h1><?highlighter on?><div id="pC" class="jN"><p>Drugs affecting the immune response are used for eczema or psoriasis. Systemic drugs acting on the immune system are used under specialist supervision. </p><p id="PHP7767"><strong>Pimecrolimus</strong> by topical application is licensed for <em>mild to moderate atopic eczema</em>. <strong>Tacrolimus</strong> is licensed for topical use in <em>moderate to severe atopic eczema</em>. Both are drugs whose long-term safety is still being evaluated and they should not usually be considered first-line treatments unless there is a specific reason to avoid or reduce the use of topical corticosteroids. Treatment with topical pimecrolimus or topical tacrolimus should be initiated only by prescribers experienced in treating atopic eczema</p><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Tacrolimus and pimecrolimus for atopic eczema (August 2004)</h3><p>Topical pimecrolimus and tacrolimus are options for atopic eczema not controlled by maximal topical corticosteroid treatment or if there is a risk of important corticosteroid side-effects (particularly skin atrophy).</p><p>Topical pimecrolimus is recommended for moderate atopic eczema on the face and neck of children aged 2–16 years and topical tacrolimus is recommended for moderate to severe atopic eczema in adults and children over 2 years. Pimecrolimus and tacrolimus should be used within their licensed indications.</p></div><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (March 2010) that tacrolimus ointment (<em>Protopic</em>®) is accepted for restricted use within NHS Scotland for the prevention of flares in those with moderate to severe atopic eczema in accordance with the licensed indications; initiation of treatment is restricted to doctors (including general practitioners) with specialist interest and experience in treating atopic eczema with immunomodulatory therapy.</p><p>For the role of topical corticosteroids in eczema, see <a title="target-block: corticosteroids: eczema" href="PHP7687-preparations-for-eczema.htm#PHP7688">section 13.5.1</a>, and for their role in psoriasis, see <a title="BNF:sub-section: Preparations for psoriasis" href="PHP7698-preparations-for-psoriasis.htm">section 13.5.2</a>. A short course of a systemic corticosteroid (section 6.3.2) can be given for eczema flares that have not improved despite appropriate topical treatment.</p><p><strong>Ciclosporin</strong> by mouth can be used for <em>severe psoriasis</em> and for <em>severe eczema</em>. <strong>Azathioprine</strong> or <strong>mycophenolate mofetil</strong> (<a title="monograph: MYCOPHENOLATE MOFETIL" href="PHP5608-mycophenolate-mofetil.htm">section 8.2.1</a>) are used for severe refractory eczema [unlicensed indication].</p><p id="PHP7768"><strong>Methotrexate</strong> can be used for <em>severe psoriasis</em>, the dose being adjusted according to severity of the condition and haematological and biochemical measurements. Folic acid (<a title="monograph: FOLIC ACID" href="PHP5874-folic-acid.htm">section 9.1.2</a>) should be given to reduce the possibility of side-effects associated with methotrexate. Folic acid can be given at a dose of 5 mg once weekly [unlicensed indication], on a different day from the methotrexate; alternative regimens of folic acid may be used in some settings.</p><p id="PHP7769"><strong>Etanercept</strong>, <strong>adalimumab</strong>, and <strong>infliximab</strong> inhibit the activity of tumour necrosis factor (TNFα). They are used for <em>severe plaque psoriasis</em> either refractory to at least 2 standard systemic treatments and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications; while either etanercept or adalimumab is considered to be the first choice in stable disease, infliximab or adalimumab may be useful when rapid disease control is required. <strong>Ustekinumab</strong> (a monoclonal antibody that inhibits interleukins 12 and 23) can be used for <em>severe plaque psoriasis</em> that has not responded to at least 2 standard systemic treatments and photochemotherapy, or when these treatments cannot be used because of intolerance or contra-indications (see also NICE guidance below). Adalimumab, etanercept, and infliximab are also licensed for psoriatic arthritis (<a title="BNF:monograph-family: Cytokine modulators" href="PHP6607-cytokine-modulators.htm">section 10.1.3</a>).</p><div class="cI"><p class="cAE">NICE guidance<span><cite><a href="PHP7766-drugs-affecting-the-immune-response.htm#ID0EAACDAA" class="tooltip ID0EAACDAA">(1)</a></cite></span></p><h3 class="cT">Adalimumab for plaque psoriasis in adults (June 2008)</h3><p>Adalimumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Adalimumab should be withdrawn if the response is not adequate after 16 weeks.</p></div><div class="cI"><p class="cAE">NICE guidance<span><cite><a href="PHP7766-drugs-affecting-the-immune-response.htm#ID0EAADCAA" class="tooltip ID0EAADCAA">(2)</a></cite></span></p><h3 class="cT">Etanercept and efalizumab for plaque psoriasis in adults (July 2006)</h3><p>Etanercept is recommended for severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Etanercept should be withdrawn if the response is not adequate after 12 weeks.</p><p>Following suspension of the marketing authorisation for efalizumab, NICE has temporarily withdrawn its guidance on the use of efalizumab for plaque psoriasis.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Infliximab for plaque psoriasis in adults (January 2008)</h3><p>Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Ustekinumab for plaque psoriasis in adults (September 2009)</h3><p>Ustekinumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Ustekinumab should be withdrawn if the response is not adequate after 16 weeks.</p><p>For patients weighing over 100 kg, the manufacturer should provide the 90-mg dose of ustekinumab at the same price as the 45-mg dose</p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP7770-azathioprine"><a href="PHP7770-azathioprine.htm" title="AZATHIOPRINE">AZATHIOPRINE</a></li><li id="_PHP7772-ciclosporin"><a href="PHP7772-ciclosporin.htm" title="CICLOSPORIN">CICLOSPORIN</a></li><li id="_PHP7776-methotrexate"><a href="PHP7776-methotrexate.htm" title="METHOTREXATE">METHOTREXATE</a></li><li id="_PHP7778-pimecrolimus"><a href="PHP7778-pimecrolimus.htm" title="PIMECROLIMUS">PIMECROLIMUS</a></li><li id="_PHP7780-tacrolimus"><a href="PHP7780-tacrolimus.htm" title="TACROLIMUS">TACROLIMUS</a></li><li id="_PHP7782-cytokine-modulators"><a href="PHP7782-cytokine-modulators.htm" title="Cytokine modulators">Cytokine modulators</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP7757-acitretin.htm">Previous: ACITRETIN</a> | <a class="top" href="PHP7766-drugs-affecting-the-immune-response.htm#">Top</a> | <a accesskey="]" href="PHP7770-azathioprine.htm">Next: AZATHIOPRINE</a> ►</div><ol class="cC"><li class="footnote" id="ID0EAACDAA"><p>The <em>Scottish Medicines Consortium</em> issued similar advice in May 2008.</p></li><li class="footnote" id="ID0EAADCAA"><p>The <em>Scottish Medicines Consortium</em> issued similar advice on the use of etanercept in adults (August 2009) and children over 6 years old (April 2012)</p></li></ol></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>